CMF
CSTL icon

Counterpoint Mutual Funds’s Castle Biosciences CSTL Stock Holding History

Counterpoint Mutual Funds’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$394K Buy
+16,510
New +$368K 0.04% 195
2026
Q1 		– Sell
-12,952
Closed -$504K – 338
2025
Q4 		$504K Buy
+12,952
New +$418K 0.04% 128
2025
Q1 		– Sell
-13,587
Closed -$362K – 316
2024
Q4 		$362K Buy
13,587
+4,688
+53% +$143K 0.05% 179
2024
Q3 		$254K Buy
+8,899
New +$226K 0.05% 212

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Counterpoint Mutual Funds's CSTL Position: Q2 2026 in Review

Counterpoint Mutual Funds opened a new position in Castle Biosciences (CSTL) in Q2 2026: 16,510 shares worth $394K. The stake represents 0.04% of the portfolio and ranks #195 among its holdings. This is a return to the name: Counterpoint Mutual Funds previously reported a position in CSTL as recently as Q4 2025.

Counterpoint Mutual Funds first reported a position in CSTL in Q3 2024 and has held it in 4 quarters since. The position peaked at $504K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Counterpoint Mutual Funds held 16,510 shares of Castle Biosciences worth $394K as of Q2 2026.
  • Castle Biosciences was a new Counterpoint Mutual Funds position in Q2 2026.
  • Castle Biosciences made up 0.04% of Counterpoint Mutual Funds's portfolio in Q2 2026, its #195 holding.
  • Counterpoint Mutual Funds first reported a position in Castle Biosciences in Q3 2024 and has held it in 4 quarters since.
  • Counterpoint Mutual Funds's Castle Biosciences position peaked at $504K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Counterpoint Mutual Funds's 13F filing for Q2 2026, filed 20 Jul 2026.